ArticleCell proliferation2023
Comprehensive analysis of pyroptosis-related gene signatures for glioblastoma immune microenvironment and target therapy.
Article in Cell proliferation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 36 citations in OpenAlex.
- Temporal dynamics in cancer immunotherapy: the interplay between circadian rhythms, tumor microenvironment, and immune checkpoint blockade.Journal of the National Cancer Center · 2026Review
- Hesperetin alleviates neuronal pyroptosis by promoting mitophagy via DHCR24/BACE1 signaling pathway after subarachnoid hemorrhage in mice.Apoptosis : an international journal on programmed cell death · 2026Article
- Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1Frontiers in immunology · 2026Article
- Article
- Integrative single-nucleus transcriptomic analysis identifies UBE2C+ proliferative tumor cells and immune-stromal regulatory crosstalk in small cell lung cancer.Frontiers in immunology · 2026Article
- DHCR24 Drives Ovarian Cancer Chemoresistance Through Lipid Raft-mediated P-gp Stabilization and STAT3 Activation.International journal of biological sciences · 2026Article
- Machine learning and bioinformatics identify and validate membrane protein biomarkers for type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Transcriptomic insights into GSDME-driven pyroptosis in head and neck cancer.Scientific reports · 2025Article
- Integrative analysis of angiogenesis-related genes highlights prognostic indicators in colorectal cancer through single-cell sequencing and immune infiltration analysis.Discover oncology · 2025Article
- Comprehensive investigation of cuproptosis-related genes in clinical features, biological characteristics, and immune microenvironment in B-cell Non-Hodgkin lymphoma.Journal of translational internal medicine · 2025Article
- The microbiome in cancer.iMeta · 2025Review
- Progress in brucellosis immune regulation inflammatory mechanisms and diagnostic advances.European journal of medical research · 2025Review
- Causal relationship among immune cells, basal cell carcinoma, and gut microbiome: a two-sample Mendelian randomization analysis and mediation analysis.Discover oncology · 2025Article
- Integration of scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells features and therapeutic targets in gastric cancer.Journal of translational medicine · 2025Article
- Single-cell insights into HNSCC tumor heterogeneity and programmed cell death pathways.Translational oncology · 2025Article
- Epithelial cells with high TOP2A expression promote cervical cancer progression by regulating the transcription factor FOXM1.Frontiers in oncology · 2025Article
- Single-cell RNA sequencing in diffuse large B-cell lymphoma: tumor heterogeneity, microenvironment, resistance, and prognostic markers.Frontiers in oncology · 2025Review
- Decoding multiple myeloma: single-cell insights into tumor heterogeneity, immune dynamics, and disease progression.Frontiers in immunology · 2025Article
- Dissecting the endothelial cell landscape in meningioma: single-cell insights intoFrontiers in immunology · 2025Article
- The role of ATF3 in precision medicine of brain arteriovenous malformation: based on endothelial cell proliferation.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Glioblastoma (GBM) is a malignant brain tumour, but its subtypes (mesenchymal, classical, and proneural) show different prognoses. Pyroptosis is a programmed cell death relating to tumour progression, but its association with GBM is poorly understood. In this work, we collected 73 GBM samples (the Xiangya GBM cohort) and reported that pyroptosis involves tumour-microglia interaction and tumour response to interferon-gamma. GBM samples were grouped into different subtypes, cluster 1 and cluster 2, based on pyroptosis-related genes. Cluster 1 samples manifested a worse prognosis and had a more complicated immune landscape than cluster 2 samples. Single-cell RNA-seq data analysis supported that cluster 1 samples respond to interferon-gamma more actively. Moreover, the machine learning algorithm screened several potential compounds, including nutlin-3, for cluster 1 samples as a novel treatment. In vitro experiments supported that cluster 1 cell line, T98G, is more sensitive to nutlin-3 than cluster 2 cell line, LN229. Nutlin-3 can trigger oxidative stress by increasing DHCR24 expression. Moreover, pyroptosis-resistant genes were upregulated in LN229, which may participate against nutlin-3. Therefore, we hypothesis that GBM may be able to upregulate pyroptosis resistant related genes to against nutlin-3-triggered cell death. In summary, we conclude that pyroptosis highly associates with GBM progression, tumour immune landscape, and tumour response to nutlin-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.